====== ML-Driven Site Scoring ======
**ML-Driven Site Scoring** refers to machine learning systems that predict clinical trial site feasibility and enrollment success by analyzing historical organizational performance data. Rather than relying on industry-wide benchmarks or generic metrics, these models generate institution-specific predictions based on each organization's unique CTMS (Clinical Trial Management System), EDC (Electronic Data Capture), and IRT (Interactive Response Technology) historical records (([[https://www.databricks.com/blog/clinical-operations-intelligence-belongs-lakehouse|Databricks - Clinical Operations Intelligence Belongs in the Lakehouse (2026]])). This approach enables more accurate site selection and resource allocation in clinical research operations.

===== Technical Framework =====
ML-Driven Site Scoring employs segmented predictive models to capture heterogeneous site performance patterns. The primary technical approach uses **TA-segmented LightGBM models**, where TA refers to therapeutic area stratification (([[https://arxiv.org/abs/1603.02754|Chen et al. - XGBoost: A Scalable Tree Boosting System (2016]])). This architecture recognizes that clinical trial site characteristics, operational capabilities, and patient populations vary significantly across different therapeutic domains—oncology sites operate under different constraints than cardiovascular sites, for instance.

The input feature space draws from three primary data sources:

* **CTMS data**: Historical trial protocol adherence, enrollment timeline accuracy, and study management metrics
* **EDC data**: Data quality metrics, query resolution times, and entry accuracy patterns
* **IRT data**: Patient retention patterns, protocol compliance tracking, and randomization distribution consistency

LightGBM (Light Gradient Boosting Machine) provides computational efficiency while handling mixed feature types and capturing nonlinear relationships between organizational capacity and enrollment outcomes (([[https://arxiv.org/abs/1606.03822|Ke et al. - LightGBM: A Fast, Distributed, Gradient Boosting Framework (2017]])). The gradient boosting approach iteratively refines predictions by correcting residual errors, enabling the model to identify subtle interaction effects between site characteristics—such as relationships between prior trial volume, staff experience, and successful patient recruitment in specific demographics.

===== Practical Applications =====
Site scoring systems support multiple critical decisions in clinical trial operations. **Site selection** represents the primary application: rather than subjectively choosing sites based on geographic availability or historical relationships, trial sponsors can use predictive scores to identify institutions with high probability of successful enrollment and data quality. A site with strong historical EDC performance and appropriate patient population demographics receives higher scores for trials requiring rapid, accurate data collection.

**Resource allocation** benefits from granular site-level predictions. Organizations can prospectively identify sites likely to experience enrollment challenges and deploy additional patient recruitment support, protocol training, or staffing resources before problems emerge. This proactive approach reduces costly mid-trial site underperformance or protocol violations.

**Portfolio optimization** across multiple simultaneous trials uses site scores to balance site workload. High-performing sites can accommodate more concurrent trials, while sites showing capability in specific therapeutic areas receive preferentially assigned studies matching their operational strengths.

===== Data Requirements and Constraints =====
Effective ML-Driven Site Scoring requires substantial historical depth. Organizations need multiple completed trials with standardized data capture across CTMS, EDC, and IRT platforms to train models with sufficient statistical power. Sites with only one or two prior trial participations may lack sufficient historical signal for reliable predictions. The temporal dimension matters critically: recent trial data (within 2-3 years) typically predicts future performance better than aggregated career-long metrics, as organizational capabilities, staff composition, and patient population dynamics change over time.

Data quality and consistency across systems poses practical challenges. CTMS implementations vary between sponsors and CROs, EDC systems use different data schemas, and IRT systems track different randomization protocols. Normalizing these heterogeneous data sources requires substantial preprocessing and domain mapping before model training (([[https://arxiv.org/abs/1909.05946|Gianfrancesco et al. - Machine Learning and Big Data in Psychiatry: Promises and Challenges (2018]])). Privacy and regulatory constraints under 21 CFR Part 11 and GDPR limit data sharing, particularly when analyses cross organizational boundaries.

===== Current Implementation Landscape =====
Leading clinical research organizations and technology platforms have begun deploying site scoring systems. Integrated platforms that provide both CTMS and EDC functionality benefit from unified data infrastructure, enabling model training without cross-system data harmonization challenges. Enterprise data lakes and clinical data warehouses support retrospective model development by centralizing historical trial data from multiple systems.

Challenges in broader adoption include initial model training effort, requirement for sufficient historical trial data, and organizational change management around data-driven site selection. Traditional site relationships and geographic preferences sometimes conflict with algorithmic recommendations, requiring stakeholder education regarding predictive accuracy.


===== See Also =====

  * [[site_feasibility_workbench|Site Feasibility Workbench]]
  * [[diversity_first_scoring|Diversity-First Scoring Dimension]]
  * [[enrollment_velocity_optimizer|Enrollment Velocity Optimizer]]
  * [[site_feasibility_workbench_vs_commercial_scoring|Site Feasibility Workbench vs Commercial Scoring Products]]
  * [[real_world_evidence_integration|Real-World Evidence Integration]]

===== References =====